주 메뉴 바로가기 본문 바로가기 하단 바로가기

Embrace Life

Global healthcare leader Celltrion will continue

its innovation to promote better and happier lives

for humanity

New Antibody for
COVID-19

Check characteristics of Covid-19, an antiviral treatment mechanism of action, current status of the treatment development and the latest news.

Learn more

Biologics
that are more approachable

Celltrion's antibody biosimilars provide patients
with high-quality yet affordable

Learn more

Pharmaceuticalsreinnovated

By venturing into the $833 billion global pharmaceutical market,
we are excited to provide affordable healthcare for more patients around the world

Learn more

Pioneering into the
future

Celltrion has shifted the pharmaceutical paradigm
with outstanding biopharmaceutical products,
Research and Development capabilities, and expertise

Learn more

Notice to shareholders

Regarding the recent news article about the Financial Services Commission’s audit inspection, Celltrion Group would like to state the following:

n  Celltrion Group learned that a daily newspaper had published an article about some matters pertaining to the progress of the ongoing audit inspection by the financial regulators.

n  Some information contained in the article does not fully reflect the truth. As the audit inspection is still ongoing, no conclusion has been drawn at this stage.

n  Celltrion Group has sincerely explained its position so far and will continue to do so in full compliance with the audit inspection process.